Keith Wilcoxen

Antibacterial agents based on the cyclic d,l-α-peptide architecture

Sara Fernandez‐Lopez, Hui-Sun Kim, Ellen C. Choi et al. · Nature · 2001 · 932 citations

Cyclic D, Medicine, Peptide Therapeutic +4

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity

Rachid Essalmani, Jaspreet Jain, Delia Susan‐Resiga et al. · Journal of Virology · 2022 · 183 citations · Full text

Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination

Philip Jones, Keith Wilcoxen, Michael Rowley et al. · Journal of Medicinal Chemistry · 2015 · 181 citations · Full text

Defective Homologous Recombination, Oral Bioavailability, Chemoprevention Strategy +16

Antiviral cyclic d,l-α-peptides: Targeting a general biochemical pathway in virus infections

W. Seth Horne, Christopher M. Wiethoff, Cui Chunli et al. · Bioorganic & Medicinal Chemistry · 2005 · 126 citations · Full text

General Biochemical Pathway, Immunology, Antiviral Response +10

Design of 2,5-Dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-<i>a</i>]pyrimidine (NBI 30775/R121919) and Structure−Activity Relationships of a Series of Potent and Orally Active Corticotropin-Releasing Factor Receptor Antagonists

Chen Chen, Keith Wilcoxen, Charles Q. Huang et al. · Journal of Medicinal Chemistry · 2004 · 117 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Crf-stimulated Acth Release +13